Protein Kinase C (PKC)

Bisindolylmaleimide X is a potent protein kinase C (PKC) inhibitor that exhibits cell-penetrating properties. It effectively inhibits the proliferation of CD4 T cells in vitro and shows antagonistic activity against cyclin-dependent kinase 2 (CDK2) with an IC50 of 200 nM. Additionally, Bisindolylmaleimide X suppresses eNOS-Ser1177 phosphorylation in human embryonic vein endothelial cells. This compound is valuable for studying mechanisms in the immune system and cardiovascular diseases.

DL-erythro-Dihydrosphingosine is a sphingosine-derived protein kinase C (PKC) inhibitor that functions by directly inhibiting phospholipase A2 (PLA2) activity. This compound also attenuates the function of Bcl-2, a protein that plays a crucial role in regulating apoptosis. Additionally, DL-erythro-Dihydrosphingosine inhibits matrix metalloproteinases (MMPs), which are involved in various cellular processes. Its unique biological activity makes it valuable for research in cancer and inflammatory disease models.

Bisindolylmaleimide IV is a selective inhibitor of protein kinase C (PKC), exhibiting IC50 values between 0.1 and 0.55 μM. It also demonstrates inhibition of protein kinase A (PKA) with IC50 ranging from 3.1 to 11.8 μM. In addition to its kinase inhibitory properties, Bisindolylmaleimide IV effectively inhibits human cytomegalovirus (HCMV) replication in cell culture, displaying an IC50 of 0.2 μM. This reagent is valuable for research applications focused on signal transduction and viral pathogenesis.

PKC-iota inhibitor 1 is an inhibitor of protein kinase C-iota (PKC-ι) with an IC50 value of 0.34 μM. This compound demonstrates significant biological activity relevant to cancer research, making it a valuable tool for investigating the role of PKC-ι in tumorigenesis and signal transduction pathways. It is suitable for studies focused on cancer biology and therapeutic interventions targeting PKC-ι.

Sangivamycin is a nucleoside analog that serves as a potent inhibitor of protein kinase C (PKC) with a Ki value of 10 μM. This compound exhibits significant antiproliferative activity against a diverse range of human cancers, making it a valuable tool for cancer research and therapeutic studies focused on PKC modulation. Its targeted mechanism of action positions Sangivamycin as a promising candidate for further exploration in cancer treatment.

PKCζ/ι Pseudosubstrate Inhibitor serves as a specific inhibitor of protein kinase C (PKC) isoforms ζ and ι. This compound exhibits broad-spectrum inhibitory effects on the PKC enzyme family, making it valuable for studies investigating the role of PKC in cell signaling and neurobiology. Additionally, it has been shown to induce memory impairment, which may be relevant for research on cognitive function and associated disorders.